FIXX News and Press, Homology Medicines Inc. From 12/22/20

Homology Medicines is a US-based genetic medicines biotech company aiming to treat rare genetic diseases with an unmet medical need. Homology Medicines has a pipeline of 1 Phase 1/2 therapeutic (HMI-102), 3-IND-enabling phase therapeutics, and 3 in the early research phase on top of t...

Gainers: BioCardia (BCDA) +102%.Arvinas (ARVN) +91%.Rubius Therapeutics (RUBY) +56%.Veru (VERU) +48%.AnPac Bio-Medical Science (ANPC) +45%.Homology Medicines (FIXX) +32%.ReneSola (SOL) +32%.Alexion Pharmaceuticals (ALXN) +31%.BioLineRx (BLRX) +30%.Big Rock Partners Acquisition (BRPA...

BioMarin is a leader in rare disease therapy discovery with multiple competitive advantages including scale, expertise, patents and relationships. Two major catalysts for 2021 provide investors with favorable risk/reward skew afforded by a low share price that should not be ignored. ...

Homology Medicines (FIXX): Q3 GAAP EPS of -$0.62 beats by $0.18.Revenue of $0.57M (+29.5% Y/Y) beats by $0.04M.Shares -0.4%.Press Release For further details see: Homology Medicines EPS beats by $0.18, beats on revenue

- Based on Positive Data , Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose Expansion Phase - - $60 Million Equity Investment from Pfizer Inc. - - Unveiled In Vivo Gene Therapy Program for Hunter Syndrome - BEDF...

Homology Medicines (FIXX) jumps 20% in premarket on xxx volume after securing equity investment of $60M from Pfizer (PFE) and purchase 5M Homology shares at $12/share.In connection with the investment, Pfizer’s Dr. Cheng will join Homology’s Scientific Advisory Board t...

BEDFORD, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Pfizer Inc. (NYSE: PFE) has agreed to make a $60 million equity investment in Homology. Pfizer has agreed to purchase 5,000,000 of Homology’s c...

Homology Medicines plunges ([[FIXX]] -21.4%) on high volume as investors appear underwhelmed with results from dose-escalation portion of the Phase 1/2 study evaluating its gene therapy (HMI-102) for phenylketonuria ((PKU)), a rare inherited disorder characterized by an inability to brea...

- Marked Reductions in Phe Observed at Two Dose s - - Achieved Goal with Plans to Advance to Randomized, Concurrently Controlled Expansion Phase of Trial...

Homology Webcast / Conference Call Scheduled for Friday, November 6 at 4:30 p.m. ET BEDFORD, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the upcoming oral presentation of data from the dose-escala...